tbuckley/cabot-search huggingface dataset:
CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone
Authors: Nicolas Goffart, Arnaud Lombard, François Lallemand, Jérôme Kroonen, Jessica Nassen, Emmanuel Di Valentin, Sharon Berendsen, Matthias Dedobbeleer, Estelle Willems, Pierre Robe, Vincent Bours, Didier Martin, Philippe Martinive, Pierre Maquet, Bernard Rogister
Journal: Neuro-Oncology (2016)

Abstract Background. Patients with glioblastoma (GBM) have an overall median survival of 15 months despite multimodal therapy. These catastrophic survival rates are to be correlated to systematic relapses that might arise from remaining glioblastoma stem cells (GSCs) left behind after surgery. In this line, it has recently been demonstrated that GSCs are able to escape the tumor mass and preferentially colonize the adult subventricular zone (SVZ). At a distance from the initial tumor site, these GSCs might therefore represent a high-quality model of clinical resilience to therapy and cancer relapses as they specifically retain tumor-initiating abilities. Method. While relying on recent findings that have validated the existence of GSCs in the human SVZ, we questioned the role of the SVZ niche as a potential GSC reservoir involved in therapeutic failure. Results. Our results demonstrate that (i) GSCs located in the SVZ are specifically resistant to radiation in vivo, (ii) these cells display enhanced mesenchymal roots that are known to be associated with cancer radioresistance, (iii) these mesenchymal traits are specifically upregulated by CXCL12 (stromal cell-derived factor-1) both in vitro and in the SVZ environment, (iv) the amount of SVZ-released CXCL12 mediates GBM resistance to radiation in vitro, and (v) interferes with the CXCL12/CXCR4 signalling system, allowing weakening of the tumor mesenchymal roots and radiosensitizing SVZ-nested GBM cells. Conclusion. Together, these data provide evidence on how the adult SVZ environment, through the release of CXCL12, supports GBM therapeutic failure and potential tumor relapse.
Prognostic Significance Of The Cytogenetic Evolution After The Hematopoietic Stem Cell Transplantation In Adult Acute Myeloid Leukemia
Authors: Mitsuhiro Yuasa, Naoyuki Uchida, Daisuke Kaji, Hikari Ota, Kazuya Ishiwata, Masanori Tsuji, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Shigeyoshi Makino, Akiko Yoneyama, Atsushi Wake, Koji Izutsu, Shuichi Taniguchi
Journal: Blood (2013)
Virtual Grief
Authors: David Wu
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Daily Eosinophil Rhythm in Mice Bearing a Transplanted Mammary Carcinoma&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Franz Halberg, Halvor Vermund, John J. Bittner
Journal: JNCI Journal of the National Cancer Institute (1956)

Daily Eosinophil Rhythm in Mice Bearing a Transplanted Mammary Carcinoma Franz Halberg, Franz Halberg Division of Cancer Biology of the Department of Physiology and Section of Radiation Therapy of the Department of Radiology, University of Minnesota Medical School, Minneapolis, Minnesota Search for other works by this author on: Oxford Academic PubMed Google Scholar Halvor Vermund, Halvor Vermund Division of Cancer Biology of the Department of Physiology and Section of Radiation Therapy of the Department of Radiology, University of Minnesota Medical School, Minneapolis, Minnesota Search for other works by this author on: Oxford Academic PubMed Google Scholar John J. Bittner John J. Bittner Division of Cancer Biology of the Department of Physiology and Section of Radiation Therapy of the Department of Radiology, University of Minnesota Medical School, Minneapolis, Minnesota Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 17, Issue 2, August 1956, Pages 139–144, https://doi.org/10.1093/jnci/17.2.139 Published: 01 August 1956 Article history Received: 05 March 1956 Published: 01 August 1956
Pim1 inhibition as a novel therapeutic strategy for Alzheimer’s disease
Authors: Ramon Velazquez, Darren M. Shaw, Antonella Caccamo, Salvatore Oddo
Journal: Molecular Neurodegeneration (2016)

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder worldwide. Clinically, AD is characterized by impairments of memory and cognitive functions. Accumulation of amyloid-β (Aβ) and neurofibrillary tangles are the prominent neuropathologies in patients with AD. Strong evidence indicates that an imbalance between production and degradation of key proteins contributes to the pathogenesis of AD. The mammalian target of rapamycin (mTOR) plays a key role in maintaining protein homeostasis as it regulates both protein synthesis and degradation. A key regulator of mTOR activity is the proline-rich AKT substrate 40 kDa (PRAS40), which directly binds to mTOR and reduces its activity. Notably, AD patients have elevated levels of phosphorylated PRAS40, which correlate with Aβ and tau pathologies as well as cognitive deficits. Physiologically, PRAS40 phosphorylation is regulated by Pim1, a protein kinase of the protoconcogene family. Here, we tested the effects of a selective Pim1 inhibitor (Pim1i), on spatial reference and working memory and AD-like pathology in 3xTg-AD mice. We have identified a Pim1i that crosses the blood brain barrier and reduces PRAS40 phosphorylation. Pim1i-treated 3xTg-AD mice performed significantly better than their vehicle treated counterparts as well as non-transgenic mice. Additionally, 3xTg-AD Pim1i-treated mice showed a reduction in soluble and insoluble Aβ40 and Aβ42 levels, as well as a 45.2 % reduction in Aβ42 plaques within the hippocampus. Furthermore, phosphorylated tau immunoreactivity was reduced in the hippocampus of Pim1i–treated 3xTg-AD mice by 38 %. Mechanistically, these changes were linked to a significant increase in proteasome activity. These results suggest that reductions in phosphorylated PRAS40 levels via Pim1 inhibition reduce Aβ and Tau pathology and rescue cognitive deficits by increasing proteasome function. Given that Pim1 inhibitors are already being tested in ongoing human clinical trials for cancer, the results presented here may open a new venue of drug discovery for AD by developing more Pim1 inhibitors.
Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients
Authors: Guillaume Dumas, Anoosha Habibi, Thierry Onimus, Jean-Claude Merle, Keyvan Razazi, Armand Mekontso Dessap, Frederic Galactéros, Marc Michel, Veronique Frémeaux Bacchi, France Noizat Pirenne, Pablo Bartolucci
Journal: Blood (2016)
Laminin-511 and laminin-521-based matrices for efficient hepatic specification of human pluripotent stem cells
Authors: Liisa K. Kanninen, Riina Harjumäki, Pasi Peltoniemi, Mariia S. Bogacheva, Tuuli Salmi, Pauliina Porola, Johanna Niklander, Tomáš Smutný, Arto Urtti, Marjo L. Yliperttula, Yan-Ru Lou
Journal: Biomaterials (2016)

Human pluripotent stem cells (hPSCs) have gained a solid foothold in basic research and drug industry as they can be used in vitro to study human development and have potential to offer limitless supply of various somatic cell types needed in drug development. Although the hepatic differentiation of hPSCs has been extensively studied, only a little attention has been paid to the role of the extracellular matrix. In this study we used laminin-511, laminin-521, and fibronectin, found in human liver progenitor cells, as culture matrices for hPSC-derived definitive endoderm cells. We observed that laminin-511 and laminin-521 either alone or in combination support the hepatic specification and that fibronectin is not a vital matrix protein for the hPSC-derived definitive endoderm cells. The expression of the laminin-511/521-specific integrins increased during the definitive endoderm induction and hepatic specification. The hepatic cells differentiated on laminin matrices showed the upregulation of liver-specific markers both at mRNA and protein levels, secreted human albumin, stored glycogen, and exhibited cytochrome P450 enzyme activity and inducibility. Altogether, we found that laminin-511 and laminin-521 can be used as stage-specific matrices to guide the hepatic specification of hPSC-derived definitive endoderm cells.
Hepatomas in Mice. I. Factors Affecting the Rapid Induction of a High Incidence of Hepatomas by &lt;italic&gt;o&lt;/italic&gt;-Aminoazotoluene
Authors: Emma Shelton
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article Hepatomas in Mice. I. Factors Affecting the Rapid Induction of a High Incidence of Hepatomas by o-Aminoazotoluene Get access Emma Shelton Emma Shelton National Cancer Institute,2Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 1, August 1955, Pages 107–127, https://doi.org/10.1093/jnci/16.1.107 Published: 01 August 1955 Article history Received: 07 January 1955 Published: 01 August 1955
P-014 Are RHOA, CSNK1A1, DVL2, FZD8 and LRP5 Genes Novel Biomarkers in the conversion from Intestinal Metaplasia to Gastric Cancer?
Authors: U. Demirci, S. Örenay Boyacıoğlu, E. Kasap, F. Bilgiç, E. Gerçeker, H. Yıldırım, A. Baykan, E. Ellidokuz, M. Yüceyar, M. Korkmaz
Journal: Annals of Oncology (2016)
Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866)
Authors: Wee-Joo Chng, Hartmut Goldschmidt, Meletios A. Dimopoulos, Philippe Moreau, Douglas Joshua, Antonio Palumbo, Thierry Facon, Heinz Ludwig, Ludek Pour, Ruben Niesvizky, Albert Oriol, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Roman Hájek
Journal: Blood (2015)
The role of circulating free DNA (cfDNA) and circulating tumor cells (CTC) in advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy (CHT).
Authors: Carlo Genova, Anna Truini, Erika Rijavec, Giulia Barletta, Federica Biello, Maria Giovanna Dal Bello, Simona Coco, Angela Alama, Irene Vanni, Francesco Grossi
Journal: Journal of Clinical Oncology (2015)

e19090 Background: cfDNA and CTC have been recently associated with metastatic and aggressive disease and might represent non-invasive prognostic markers. Our aim was to assess whether the variation of cfDNA and CTC might predict the objective response, progression-free survival (PFS) and survival in patients with advanced NSCLC receiving 1stline CHT with cisplatin/carboplatin plus pemetrexed (non-squamous histology) or gemcitabine (squamous histology). Methods: Peripheral blood samples and computed tomography (CT)-scans were obtained at baseline and after every two cycles from 70 patients treated with 1st line CHT; CTC were isolated by size using a filtration-based device (ScreenCell) and characterized and enumerated through H&E staining and immunofluorescence, whereas cfDNA was quantified by qPCR. Radiological responses were assessed by CT-scans according to RECIST v.1.1. Results: Patients’ characteristics: median age 67 (44-80); 69% males, 31% females; non-squamous: 90%, squamous: 10%; no patient harbored activating mutations of EGFR or ALK translocation. Median cfDNA at baseline: 76.8 copy number, median CTC at baseline: 14/3ml blood. Median PFS and OS were 5.0 and 7.5 months, respectively. Baseline cfDNA quantification significantly predicted PFS (1st vs. 4th quartile: 7 vs. 3 months) and OS (1st vs. 4thquartile: 8 vs. 5 months), whereas baseline CTC count alone did not predict outcome. The cfDNA decrease/increase after 2 CHT cycles was able to predict OS (-30% vs. +30%: 12 vs. 9.5 months), the same trend for OS was observed using CTC variation (-30% vs. +30%: 8 vs. 5 months). Interestingly, in patients with high number of baseline CTC ( > 25/3 ml), their variation (-30% vs. +30%) significantly predicted prognosis in terms of PFS (5.5 vs. 1.0 months) and OS (9 vs. 2.0 months). Conclusions: Althoughthe evaluation of cfDNA and CTC did not anticipate CT-scans result, it could be used as additional non-invasive approach of disease monitoring; in particular, CTC count was reported as a reliable prognostic marker in patients with high baseline CTC number. ClinicalTrials.gov n° NCT02055144 Clinical trial information: NCT02055144.
Clinical characteristics and public health management of invasive meningococcal group W disease in the East Midlands region of England, United Kingdom, 2011 to 2013
Authors: Jane Bethea, Sophia Makki, Steve Gray, Vanessa MacGregor, Shamez Ladhani
Journal: Eurosurveillance (2016)

In England and Wales, meningococcal disease caused by group W has historically been associated with outbreaks of disease among travellers to high-risk countries. Following a large outbreak associated with travel to the Hajj in 2000, the number of cases declined and, in 2008, only 19 laboratory-confirmed cases were identified nationally. In 2013, in the East Midlands region of England, eight cases of meningococcal disease caused by this serogroup were recorded, compared with six from 2011 to 2012. To explore this further, data for all cases with a date of onset between 1 January 2011 and 31 December 2013 were collected. Data collected included geographical location, clinical presentation and outcome. Fourteen cases were identified; two died as a result of their illness and two developed long-term health problems. No commonality in terms of geographical location, shared space or activities was identified, suggesting that group W is circulating endemically with local transmission. Clinical presentation was variable. Half presented with symptoms not typical of a classical meningococcal disease, including two cases of cellulitis, which may have implications for clinicians, in terms of timely identification and treatment, and public health specialists, for offering timely antibiotic chemoprophylaxis to close contacts.
Randomized phase II study comparing the MET inhibitor cabozantinib to temozolomide (TMZ) or dacarbazine (DTIC) in ocular melanoma: A091201.
Authors: Jason John Luke, Jacob B Allred, Laura E. Horvath, Bruno R. Bastos, Charles Erlichman, Gary K. Schwartz
Journal: Journal of Clinical Oncology (2015)

TPS9087 Background: Ocular melanoma has been described to express the receptor tyrosine kinase MET in up to 80% of specimens and preclinical data suggests that MET inhibitors reduce proliferation and metastatic potential in cell lines and murine xenografts. Cabozantinib is a receptor tyrosine kinase inhibitor with significant inhibitory activity against MET and VEGFR2 (among other targets). Cabozantinib was associated with a median progression-free survival (mPFS) of 4.8 months in final follow up of the ocular melanoma cohort of the cabozantinib randomized discontinuation clinical trial. Notably, the MEK inhibitor selumetinib was determined to deliver mPFS of 3.9 months in a randomized phase II study. Methods: This is a national (Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NCIC Clinical Trials Group) open-label phase II study comparing cabozantinib with TMZ/DTIC in advanced ocular melanoma (clinicaltrials.gov: NCT01835145). The study randomizes patients 2:1 to cabozantinib and facilitates cross-over from the chemotherapy arm to cabozantinib at progression of disease. Eligibility is for any line of therapy and allows for prior treatment with MEK inhibitor or immunotherapy. Other eligibility includes biopsy proven metastatic ocular melanoma, ECOG 0-1 and adequate organ function (modified for elevated liver function tests related to hepatic metastases). The primary endpoint is PFS at 4 months with secondary endpoints evaluating RECIST response rate, PFS, overall survival and correlation of the primary endpoint with pre-treatment tumor tissue MET expression by IHC. The study is open to accrual via the Cancer Trials Support Unit (CTSU) of NCI to any cooperative group member site. Recruitment is on-going (target 69 patients). Clinical trial information: NCT01835145 or Alliance for Clinical Trials in Oncology # A091201. Clinical trial information: NCT01835145.
Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis
Authors: Kasper Fjellhaugen Hjuler, Morten Bøttcher, Christian Vestergaard, Hans Erik Bøtker, Lars Iversen, Knud Kragballe
Journal: JAMA Dermatology (2016)

Inflammatory pathways of psoriasis share similarities with the mechanisms identified in atherosclerosis, and the association between psoriasis and cardiovascular disease due to accelerated coronary artery disease is well established. The effect of anti-inflammatory drugs on the development of coronary atherosclerosis remains essentially unknown.To investigate the association of biological therapy with changes in coronary artery disease progression, measured by repeated coronary computed tomography (CT).This single-center prospective, controlled, observer-blinded clinical study at a tertiary dermatology university hospital clinic enrolled patients with severe psoriasis initiating biological therapy and matched controls not receiving systemic therapy from April 11, 2011, through June 30, 2014.Biological therapy approved for psoriasis (adalimumab, etanercept, infliximab, ustekinumab) with the possibility to switch between treatments to ensure tight control of inflammation.Patients underwent noncontrast coronary artery calcium (CAC) CT and contrast-enhanced coronary CT angiography at baseline and after 13 months of follow-up. Changes in CAC score, number of coronary plaques, severity of narrowing, composition, and vessel wall volume were measured.There were 28 treated patients (mean [SD] age, 49.2 [10.2] years; 71% men; mean [SD] Psoriasis Area Severity Index [PASI], 15.4 [4.3]) and 28 controls (mean [SD] age, 52.8 [10.6] years; 71% men; mean [SD] PASI, 12.4 [3.9]). The CAC scores remained stable in the intervention group (mean [SD] yearly CAC change, -16 [56]; P = .15) and progressed in the control group (14 [29]; P = .02) (intervention vs controls: P = .02). The number of segments with luminal abnormalities remained unchanged in both groups. The severity of luminal narrowing in the diseased segments was unchanged in the intervention group (Wilcoxon W = 76, n = 483, P = .39) but increased at follow-up in the control group (Wilcoxon W = 281, n = 414, P = .02). Automated vessel wall volume index remained unchanged from baseline to follow-up in the intervention group (mean [SD] baseline, 7.1 [1.5], follow-up, 7.1 [1.7]; P = .91), while controls demonstrated statistically nonsignificant progression (baseline, 8.3 [1.6], follow-up, 8.9 [2.2]; P = .06).Clinically effective treatment with biologic agents was associated with reduced coronary artery disease progression in patients with severe psoriasis. These findings support a beneficial effect of biologic anti-inflammatory agents in preventing cardiovascular disease progression in addition to disease control in inflammatory diseases.
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Authors: Laurie H Sehn, Neil Chua, Jiri Mayer, Gregg Dueck, Marek Trněný, Kamal Bouabdallah, Nathan Fowler, Vincent Delwail, Oliver Press, Gilles Salles, John Gribben, Anne Lennard, Pieternella J Lugtenburg, Natalie Dimier, Elisabeth Wassner-Fritsch, Günter Fingerle-Rowson, Bruce D Cheson
Journal: The Lancet Oncology (2016)
대한간학회지 제6차 춘계학술대회 초록집 : 구연 ; DNA Chip을 이용한 간세포암에서 과발현되는 유전자 검색
Authors: 윤정환 ( Yun Jeong Hwan ), 김태헌 ( Kim Tae Heon ), 박웅양 ( Park Ung Yang ), 이효석 ( Lee Hyo Seog ), 김정룡 ( Kim Jeong Lyong )
Journal: Clinical and Molecular Hepatology (2000)
Possible mechanisms of the crosstalk between Langerhans cells and regulatory T cells in extramammary Paget disease by receptor activator of nuclear factor kappa B ( <scp>RANK</scp> ) ligand/ <scp>RANK</scp> pathways
Authors: T. Fujimura, Y. Kambayashi, S. Furudate, A. Kakizaki, T. Hidaka, S. Aiba
Journal: British Journal of Dermatology (2016)

Extramammary Paget disease (EMPD) is a skin adenocarcinoma of apocrine gland origin, in which Paget cells express receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) and matrix metalloproteinase (MMP)-7, and release soluble (s)RANKL into the tumour microenvironment. We previously reported that about 60% of the RANK+ cells among the stromal cells are M2 macrophages, but the identity of the remaining population of RANK+ cells is still unknown.To investigate the unknown subpopulation of RANK-expressing cells in EMPD.The main population of RANK-expressing cells in the epidermis was composed of epidermal Langerhans cells (LCs). To explore the effects of RANKL on LCs, we stimulated LCs generated from human CD34+ hematopoietic progenitor cells with graded concentrations of sRANKL. To further examine the correlation between LCs and regulatory T cells (Tregs) in EMPD, we employed immunohistochemical staining.sRANKL stimulation was shown to augment the production of C-C motif chemokine ligand 17 (CCL17) from LCs. We additionally demonstrated CCL17 expression by CD1a+ LCs in EMPD in an immunofluorescence study. Spearman's rank correlation test confirmed a correlation between the number of LCs and the number of Foxp3+ Tregs in the lesional skin of invasive EMPD. In addition, the numbers of Foxp3+ Tregs in the sentinel lymph nodes of metastatic EMPD were significantly higher than those of metastatic melanoma, which did not express RANKL.The findings suggest that the RANKL/RANK pathway in EMPD might contribute to the recruitment of Tregs and to maintenance of the tumour microenvironment.
Juvenile court versus child guidance referral: psychosocial and parental factors
Authors: S S Shanok, D O Lewis
Journal: American Journal of Psychiatry (1977)

The authors compared the psychiatric symptoms, socioeconomic status, family structure, family size, and occurrence of treated parental mental illness in 136 children referred to a juvenile court and 82 children referred to a child guidance clinic. The prevalence of psychiatric and organic symptoms and treated parental psychopathology in both groups of children did not differ significantly. Juvenile court clinic children, however, tended to come from larger families and to lack a biological mother in the home. The authors explore explanations for the routing of sick children to the juvenile court rather than to a treatment facility.